Antibiotics have been pivotal in combating bacterial infections, but the emergence of bacterial biofilms presents a significant challenge. These resilient microbial communities, encased in protective matrices, are a hallmark of chronic infections such as those in cystic fibrosis lungs. Biofilm-associated bacteria exhibit adaptive resistance (tolerance), enduring antibiotic concentrations up to 1000 times higher than those required to target free-floating cells. This tolerance represents a critical obstacle in the fight against antimicrobial resistance.

Currently, no specific treatments effectively target biofilm-associated infections. Compounding the challenge, polymicrobial biofilms—formed by multiple bacterial species coexisting in a shared environment—further complicate disease dynamics and treatment strategies. Our research aims to decipher the complexities of polymicrobial biofilms, investigating their formation, persistence, and resistance mechanisms to uncover new therapeutic approaches.

This work represents a vital step toward addressing one of the most pressing issues in modern medicine: overcoming the resilience of biofilm-associated infections and redefining the future of antibiotic therapies.